3 Stocks Pushing The Health Services Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 28 points (-0.2%) at 13,217 as of Thursday, Dec. 13, 2012, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,125 issues advancing vs. 1,742 declining with 157 unchanged.

The Health Services industry currently is unchanged today versus the S&P 500, which is down 0.3%. A company within the industry that fell today was Smith & Nephew ( SNN), up 0.9%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:

3. Mednax ( MD) is one of the companies pushing the Health Services industry higher today. As of noon trading, Mednax is up $0.87 (1.1%) to $79.88 on light volume Thus far, 136,997 shares of Mednax exchanged hands as compared to its average daily volume of 390,500 shares. The stock has ranged in price between $78.81-$80.28 after having opened the day at $79.05 as compared to the previous trading day's close of $79.01.

MEDNAX, Inc., together with its subsidiaries, provides neonatal, maternal-fetal, other pediatric subspecialties, and anesthesia physician services in the United States and Puerto Rico. Mednax has a market cap of $3.9 billion and is part of the health care sector. The company has a P/E ratio of 16.3, below the S&P 500 P/E ratio of 17.7. Shares are up 9.4% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Mednax a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Mednax Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Why the Boardroom Doesn't Need Ivy League Degrees

Mednax: Solid Growth at a Good Price

Analysts' Actions -- Kimberly-Clark, IberiaBank, Ionis Pharma, Actuant and More

How to Invest in Your Favorite MD